Defense Threat Reduction Agency

ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome

Retrieved on: 
Thursday, March 28, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Radiation, Acute radiation syndrome, Attack, ARS, Inflammation, Education, Chronic obstructive pulmonary disease, RNCP, USUHS, Virus, IND, European Medicines Agency, Outline of health sciences, Nausea, Accident, Hypoxia (medical), NIAID, Defense Threat Reduction Agency, AFRRI, HIE, Vaccine, Collection, Vomiting, Food, FDA, Defense, Infection, Peptide, Pharmaceutical industry

“We are very pleased to partner with NIAID and AFRRI to evaluate ReAlta’s lead drug candidate, RLS-0071, as a radiation countermeasure for GI-ARS,” says Dr. Ulrich Thienel, Chief Executive Officer of ReAlta.

Key Points: 
  • “We are very pleased to partner with NIAID and AFRRI to evaluate ReAlta’s lead drug candidate, RLS-0071, as a radiation countermeasure for GI-ARS,” says Dr. Ulrich Thienel, Chief Executive Officer of ReAlta.
  • AFRRI is unique and powerful radiobiological research institute, with six decades of active, robust, and outstanding support to the U.S. Department of Defense through research, reach-back, and education.
  • It is the only U. S. Department of Defense medical R&D facility dedicated solely to nuclear and radiological defense.
  • ReAlta Life Sciences, Inc. is a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life threatening acute inflammatory and rare diseases.

NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University

Retrieved on: 
Thursday, December 21, 2023
Work, Annual report, Research, CDMO, DTRA, Defense Threat Reduction Agency, Growth, NIH, Scorpius

DURHAM, N.C., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced its Scorpius BioManufacturing subsidiary (“Scorpius”) completed a demonstration run in the Company’s process development lab for a microbial vaccine program developed by a top-tier research university that is NIH and DTRA (Defense Threat Reduction Agency) funded.

Key Points: 
  • Jeff Wolf, CEO of NightHawk, commented, “This first phase of a multi-million-dollar project was particularly noteworthy, as we achieved a successful demonstration run following a prior failed attempt by a competitor CDMO.
  • The complexity of the project led this top-tier university to choose Scorpius, drawn by our more engaged management approach and accelerated development timeline.
  • The successful completion of this demonstration run showcases our team's dedication and expertise, and represents an important step in advancing our relationship with this nationally renowned university.
  • The next phase of this project will include scaling up to cGMP manufacturing to support a phase 1 infectious disease trial.

Multiagency Investment In AI-Driven Data Harmonization

Retrieved on: 
Wednesday, December 13, 2023
Transfer, Defense Threat Reduction Agency, National academy, DARPA, Risk, Collection, Data, DTRA, Artificial intelligence, Defense, Small business, ARPA, Bacteria, Human services, Friend or Foe, Netria, PathEngine, Soil, STTR, Twenty questions, Vaccine

Initially developed through a DARPA Small Business Technology Transfer award (STTR), PathEngine will leverage data generated by the Defense Threat Reduction Agency (DTRA) to increase pathogenicity prediction accuracy of unknown threats using revolutionary advances in automated data curation and multi-omics data integration.

Key Points: 
  • Initially developed through a DARPA Small Business Technology Transfer award (STTR), PathEngine will leverage data generated by the Defense Threat Reduction Agency (DTRA) to increase pathogenicity prediction accuracy of unknown threats using revolutionary advances in automated data curation and multi-omics data integration.
  • While incorporating multi-modal data can be advantageous, providing multiple perspectives, it is seldom used as collection, curation, and harmonization of multi-modal metadata and data remains a significant challenge for downstream analysis.
  • Netrias' AI Driven Data Harmonization capabilities streamline this process so that researchers can focus on the experiments and PathEngine will automatically curate the data.
  • With a curated dataset, a multi-stage AI model then analyzes the data to predict the pathogenic potential of the threat.

Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy

Retrieved on: 
Wednesday, October 25, 2023
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, IND, Bioterrorism, Investigational New Drug, Infection, Francisella tularensis, Drug development, Pharming, DTRA, Defense Threat Reduction Agency, Partnership, TSX, Tularemia, Pharmaceutical industry, USAFA

ATI-1701 is the Company’s potential first-in-class vaccine candidate for the prevention of infection with Francisella tularensis, the causative agent of tularemia and a top-priority biothreat.

Key Points: 
  • ATI-1701 is the Company’s potential first-in-class vaccine candidate for the prevention of infection with Francisella tularensis, the causative agent of tularemia and a top-priority biothreat.
  • With this additional 6.6 million award, Appili’s ATI-1701 program has been awarded the total US$14 million in USAFA funding commitments announced on May 8, 2023.
  • In May 2023, Appili was awarded the first stage of funding commitment from USAFA of US$7.3 million.
  • Appili has also entered into an agreement with its lender whereby if needed, Appili has obtained temporary waivers of a minimum cash balance requirement.

New to The Street Signs Vector Space Biosciences, Inc. to 6-Part Media Series

Retrieved on: 
Tuesday, October 10, 2023
Government, Newsmax TV, Probability, Biology, New Haven State Street station, Microsoft, Medicine, Partnership, Defense Threat Reduction Agency, Television, Moon, Bloomberg Television, Travel, Ames Research Center, LEO, Entrepreneurship, Bloomberg, DTRA, CubeSat, Fox Business, Vector, Human, Social media, NASA, NVIDIA, AI, Street, Oracle, Mars

NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- FMW Media Corp. announces that its New to The Street business TV show will feature Vector Space Biosciences, Inc .

Key Points: 
  • NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- FMW Media Corp. announces that its New to The Street business TV show will feature Vector Space Biosciences, Inc .
  • The New to The Street TV's social media team and its television network partners will reshare media content, creating a platform to educate televised viewers and others about Vector.
  • Vince Caruso, CEO/Producer of New to The Street, states, "I am excited to have Vector Space Biosciences, Inc. on the show.
  • New to The Street's televised interviews with Vector Space Biosciences, Inc.'s management, "To Be Announced," before airings on Newsmax TV , Fox Business Network , and Bloomberg TV .

Parsons Awarded $53M Defense Threat Reduction Agency Task Order For International Security Solutions

Retrieved on: 
Monday, October 9, 2023
College of Engineering (KNUST), Weapon, Parsons, IDIQ, NYSE, Assessment, Parsons Corporation, PSN, Defense Threat Reduction Agency, Proliferation Security Initiative, State bureau of investigation, Simulation, Federal Bureau of Investigation, DTRA, ICP, Maintenance, DOD, United States Secretary of Homeland Security, PSI, WMD, Atmosphere, Risk management, Exercise

CHANTILLY, Va., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) announced today that the company was awarded a task order by the Defense Threat Reduction Agency (DTRA) under the Assessment, Exercise, Modeling and Simulation, and Support (AEMSS) indefinite-delivery, indefinite-quantity (IDIQ) multiple award task order contract (MATOC).

Key Points: 
  • CHANTILLY, Va., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) announced today that the company was awarded a task order by the Defense Threat Reduction Agency (DTRA) under the Assessment, Exercise, Modeling and Simulation, and Support (AEMSS) indefinite-delivery, indefinite-quantity (IDIQ) multiple award task order contract (MATOC).
  • Under this task order, Parsons will provide training, equipment, and subsequent maintenance to DTRA.
  • “Through our global security solutions, we empower our customers to counter and mitigate vulnerabilities and threats,” said Jon Moretta, president, Engineered Systems, for Parsons.
  • This award is Parsons’ second task order under the AEMSS IDIQ MATOC and expands the company’s relationship with DTRA.

Robin Champ Joins LBL Strategies as Vice President, Strategic Foresight

Retrieved on: 
Thursday, October 12, 2023
Consulting, Veterans, Defense, Professional Services, Small Business, Army, Secret Service, United States Army, Interest, Defense Threat Reduction Agency, Strategic foresight, Champ, Robin, The Secret Service, Management

LBL Strategies , a certified veteran-owned small business specializing in strategy and foresight training and consulting, proudly announces the appointment of Robin Champ as its first Vice President for Strategic Foresight.

Key Points: 
  • LBL Strategies , a certified veteran-owned small business specializing in strategy and foresight training and consulting, proudly announces the appointment of Robin Champ as its first Vice President for Strategic Foresight.
  • Champ brings an impressive 20-year track record of foresight and strategy expertise to her new role.
  • She also served as Co-chair for the Federal Foresight Community of Interest and is a proclaimed U.S. Army “Mad Scientist.”
    “We are thrilled to welcome Robin to LBL Strategies.
  • Robin is an advocate for organizational performance, a certified Strategic Management Professional, an outstanding instructor, and possesses extensive experience that will yield exceptional results for customers,” expressed Randall Rollinson, President of LBL Strategies.

Appili Therapeutics Presents at the 10th International Tularemia Conference

Retrieved on: 
Wednesday, September 27, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Infection, Partnership, Drug development, Defense Threat Reduction Agency, Tularemia, Government, TSX, United States Department of the Air Force, Conference, Pharmaceutical industry

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Carl Gelhaus, Ph.D., Director of Non-Clinical Research, and key members of Appili’s scientific team, will participate at the 10th International Tularemia Conference, from September 24 to 26, 2023.

Key Points: 
  • Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Carl Gelhaus, Ph.D., Director of Non-Clinical Research, and key members of Appili’s scientific team, will participate at the 10th International Tularemia Conference, from September 24 to 26, 2023.
  • Dr. Gelhaus will present an update on Appili’s biodefense vaccine program ATI-1701 .
  • “The International Tularemia Conference is the premier tularemia conference in the world, and we look forward to sharing the progress we have made on ATI-1701 over the past several years and strengthen relationships with leading tularemia clinicians and researchers,” said Dr. Gelhaus.
  • Presentation details are as follows:
    Appili management will also be conducting in-person meetings throughout the conference.

AiRANACULUS® Awarded Defense Department Contract for System to Predict Personnel Exposure to Chemical and Biological Threats

Retrieved on: 
Tuesday, September 26, 2023
Exercise, Artificial intelligence, Deep learning, Defense Threat Reduction Agency, Vital signs, Infection, United States Department of Defense, Machine learning, Public, Sleep deprivation, Medical device

CHELMSFORD, Mass., Sept. 26, 2023 /PRNewswire-PRWeb/ -- AiRANACULUS®, a private, Massachusetts-based technology company providing state-of-the-art Artificial Intelligence (AI) and Machine Learning (ML) solutions, announced that it has received a U.S. Department of Defense contract for a prototype software system to provide warfighters with predictive early warning of exposure to chemical and biological threats.

Key Points: 
  • Under its contract with the Defense Threat Reduction Agency, AiRANACULUS will demonstrate an AI-based platform to alert warfighters of probable exposure.
  • The platform will leverage existing wearable device technology to capture and assess basic signs of bodily function such as heart rhythms, respiration rates, and oxygen levels.
  • AiRANACULUS will apply a variety of deep learning and other artificial intelligence techniques to those vital signs to make high confidence predictions of which individuals were likely exposed to chemical and/or biological threats, providing early warning before larger exposure.
  • "Exposure to chemical or biological agents may not be perceived until it's too late," said Dr. Kakali Bandyopadhyay, Chief Scientist to AiRANACULUS.

EverGlade Consulting Funding Alert: DTRA BAA Outlines New Opportunity to Identify and Counter Weapons of Mass Destruction (WMD) through the Strategic Trends Research Initiative

Retrieved on: 
Monday, September 25, 2023
ASPR, Global Strategic Trends Programme, Broad Agency Announcement, BAA, Research, DTRA, Defense Threat Reduction Agency, DARPA, STRI, Mass, Weapon, Federation, Chatham House Rule, BARDA, NIH, WMD, Retail

CHARLESTON, S.C., Sept. 25, 2023 /PRNewswire/ -- The Defense Threat Reduction Agency (DTRA) has amended its Broad Agency Announcement (BAA) to offer new funding opportunities through the Strategic Trends Research Initiative (STRI) for identifying and countering Weapons of Mass Destruction (WMD), defined as nuclear, chemical, and/or biological weapons. DTRA's Strategic Integration Directorate (SI) leads in generating insights and outlining future threats, focusing on strategic dialogues and research studies through STRI, enabling a profound understanding of emerging threats and fostering relationships with allies and non-traditional partners to counter WMD-related security challenges.

Key Points: 
  • CHARLESTON, S.C., Sept. 25, 2023 /PRNewswire/ -- The Defense Threat Reduction Agency (DTRA) has amended its Broad Agency Announcement (BAA) to offer new funding opportunities through the Strategic Trends Research Initiative (STRI) for identifying and countering Weapons of Mass Destruction (WMD), defined as nuclear, chemical, and/or biological weapons.
  • The amendment delineates two thrust areas: Thrust Area 1 emphasizes WMD-relevant strategic dialogues under the "Chatham House Rule," facilitating confidential discussions to gain strategic insights and strengthen partnerships.
  • DTRA will conduct a virtual Research Topic Information Session on October 4, 2023, allowing participants to inquire about research priorities and other BAA-related topics.
  • EverGlade Consulting is a national consulting firm helping clients navigate the federal landscape.